Angelo A. Licata, MD, PhD Department of Endocrinology, Cleveland Clinic
Angelina V. Ciaccia, PhD Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
Mayme Wong, PhD Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
Michael W. Draper, MD, PhD Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
Address: Angelo A. Licata, MD, PhD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; licataa@ccf.org
Dr. Licata has received grant support from Eli Lilly and Company, which manufactures raloxifene.
Drs. Ciaccia, Wong, and Draper are employees of Eli Lilly and Company.
ABSTRACT
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
